Boston Scientific Corporation $BSX Shares Acquired by Swedbank AB

Swedbank AB boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 21.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 3,429,844 shares of the medical equipment provider’s stock after acquiring an additional 611,167 shares during the period. Swedbank AB’s holdings in Boston Scientific were worth $327,036,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Claret Asset Management Corp lifted its holdings in Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its stake in Boston Scientific by 5.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 103 shares during the period. Kera Capital Partners Inc. boosted its holdings in Boston Scientific by 3.3% in the 3rd quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock valued at $333,000 after purchasing an additional 109 shares during the last quarter. Crews Bank & Trust grew its stake in shares of Boston Scientific by 11.6% in the 3rd quarter. Crews Bank & Trust now owns 1,061 shares of the medical equipment provider’s stock valued at $104,000 after buying an additional 110 shares during the period. Finally, Outfitters Financial LLC increased its holdings in shares of Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after buying an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BSX shares. Truist Financial decreased their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Morgan Stanley reduced their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Finally, Citigroup reduced their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Price Performance

BSX opened at $55.98 on Wednesday. The stock’s 50-day moving average price is $66.69 and its 200 day moving average price is $84.28. Boston Scientific Corporation has a 12-month low of $55.88 and a 12-month high of $109.50. The firm has a market cap of $83.20 billion, a price-to-earnings ratio of 23.42, a PEG ratio of 1.04 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.